Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-PluReceptor-NK cells
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
AD-PluReceptor-NK cells are an investigational allogeneic natural killer (NK) cell therapy developed at the MD Anderson Cancer Center. These cells are engineered using the proprietary "PluReceptor" (Plug-and-Play) platform, which features a universal high-affinity chimeric receptor, typically an engineered version of the Fc gamma receptor IIIa (CD16a/FCGR3A). This modular design allows the NK cells to be "plugged" into various monoclonal antibodies, effectively redirecting their cytotoxic activity toward specific antigens via antibody-dependent cellular cytotoxicity (ADCC). In current clinical studies for autoimmune disorders, these cells are being evaluated in combination with the anti-CD19 monoclonal antibody tafasitamab to achieve deep depletion of B cells. The cells are often further modified to express cytokines like IL-15 to enhance their survival, expansion, and persistence in the recipient's circulatory system.
- Other names
- AD-PluReceptorPluReceptor NK cellsAllogeneic Donor PluReceptor-NK cells
02
Targets
CD19 (B lymphocyte antigen CD19)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on AD-PluReceptor-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-PluReceptor-NK cells.